Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 308Lung Neoplasms 70Neoplasms 50Neoplasm Metastasis 33Parkinson Disease 4, Autosomal Dominant Lewy Body 20Colorectal Neoplasms 20Carcinoma 20Mesothelioma 15Breast Neoplasms 15Mesothelioma, Malignant 13Small Cell Lung Carcinoma 11Melanoma 10Adenocarcinoma 10Neoplasms by Site 9Adenocarcinoma of Lung 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Lung Diseases 7Thoracic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Non-Squamous Non-Small Cell Lung Cancer 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Respiratory Tract Diseases 5Recurrence 5Rectal Neoplasms 5Neoplasms by Histologic Type 5NSCLC 5Head and Neck Neoplasms 5Endometrial Neoplasms 5

Interventions

Pemetrexed 2Carboplatin 2camrelizumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Non Squamous Non Small Cell Lung Cancer × Pemetrexed × Clear all
NCT06687369 2026-03-11

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

mAbxience Research S.L.

Phase 3 Recruiting
726 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

CrystalGenomics, Inc.

Phase 2 Recruiting
60 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡